Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ZFP36L1
REST API REST API
Homo sapiens
ZFP36L1 is differentially expressed in 385 experiments: 172 organism parts: ovary, uterus, ... (170 more);, 222 disease states: normal, control, ... (220 more);, 143 cell types 470 cell lines 52 compound treatments and 90 other conditions.
Synonyms BRF1, Berg36, ERF1, RNF162B, cMG1, TIS11B
Orthologs TIS11 (Saccharomyces cerevisiae)   zfp36l1b (Danio rerio)   zfp36l1a (Danio rerio)   A7MB98_BOVIN (Bos taurus)   TISB_RAT (Rattus norvegicus)   Zfp36l1 (Mus musculus)   Q4H2G7_CIOIN (Ciona intestinalis)   CTH1 (Saccharomyces cerevisiae)   Tis11 (Drosophila melanogaster)   zfp36l1 (Xenopus laevis)   ZFP36L1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, DNA binding, mRNA catabolic process, protein binding, regulation of transcription, DNA-dependent, cytoplasm, transcription, DNA-dependent, metal ion binding, nucleic acid binding, RNA metabolic process, regulation of translation, regulation of mRNA stability, mRNA binding, nucleus, nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay, zinc ion binding, mRNA metabolic process, AU-rich element binding, vasculogenesis, sequence-specific DNA binding transcription factor activity, T cell differentiation in thymus
InterPro Term Znf_CCCH, Tis11B_N
UniProt Accession Q07352, B4E1N3, B4DG15
Search EB-eye ENSG00000185650
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (48 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
SW480
4
E-MEXP-1014, E-GEOD-2509, E-GEOD-18005, E-MTAB-37
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
SNU1
2
E-MTAB-37, E-GEOD-15460
A549
2
E-GEOD-3202, E-GEOD-6013
BT-474
2
E-GEOD-3529, E-GEOD-5823
464 more value(s).


Cell type

studied in E-GEOD-20193, E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (68 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
memory B cell
2
E-MEXP-2360, E-TABM-702
monocyte
2
3
E-MEXP-583, E-MEXP-2019, E-GEOD-11755, E-GEOD-5099, E-GEOD-22373 ... (5 experiments)
wild_type
1
E-GEOD-20193
T-cell
1
E-GEOD-10820
hMOF knock-down
1
E-GEOD-20193
137 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-2280, ... (77 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MEXP-1331, E-MTAB-62, E-MTAB-37
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
prostate carcinoma
1
3
E-MEXP-2034, E-GEOD-96, E-MTAB-62, E-MTAB-37
papillary thyroid carcinoma
2
E-GEOD-3678, E-GEOD-3467
prostate cancer
2
E-MTAB-62, E-GEOD-6919
colorectal carcinoma
2
E-GEOD-23878, E-GEOD-4045
216 more value(s).


Compound treatment

studied in E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-MEXP-1958, ... (32 experiments)

Factor Value U/D Experiments
none
1
14
E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-GEOD-20719, E-GEOD-22309, ... (15 experiments)
lipopolysaccharide
2
E-GEOD-3720, E-MEXP-1958
glutamine
2
E-MEXP-1335, E-MEXP-941
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
1
E-GEOD-6932
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
N-nitrosodimethylamine
1
E-GEOD-6907
46 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
58.98
1
1
E-TABM-325


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (12 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22541, E-GEOD-2509, ... (11 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-TABM-601, E-MEXP-1838, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, E-GEOD-837, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (44 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (6 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, ... (9 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, ... (10 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428, E-GEOD-12710

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-16193, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-22541, E-TABM-43, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.453 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM